Self-medication of dyspepsia: how appropriate is it?

Scand J Gastroenterol

Stakes (National Research and Development Centre for Welfare and Health), Health Services Research Unit, Helsinki, Finland.

Published: September 1997

Background: The scope of self-medication is increasing in many countries, and drugs for dyspepsia are a popular group for deregulative activities. This study investigated what kind of upper gastrointestinal symptoms people self-medicate and how appropriate this self-medication is.

Methods: An anonymous questionnaire was give to 50 consecutive customers buying antacids, alginates, or sucralfates in 10 pharmacies in the capital area in Finland in 1995. In half of the pharmacies the questionnaire was returned by mail, and in the other half the questionnaire was filled out at the pharmacy. The response rate was 53% (n = 292).

Results: The commonest reasons for self-medication were heartburn (88%), gastrointestinal pain (31%), and acid regurgitation (32%). Seventy-five per cent of respondents had used dyspepsia drugs for more than a year. The commonest way to self-medicate was to interchange regular and occasional use. Knowledge about the proper use of dyspepsia drugs was poor, and 6% of respondents had symptoms contraindicating self-medication but had not visited a physician during the past year. Patients more than 60 years old were especially at risk of potential inappropriate use.

Conclusions: Over-the-counter (OTC) drugs for dyspepsia are likely to be used improperly. A physician's advice on the use of OTC dyspepsia drugs, in addition to detailed printed information about drug action and proper administration, would be important means to guarantee appropriate use of these drugs.

Download full-text PDF

Source
http://dx.doi.org/10.3109/00365529709011191DOI Listing

Publication Analysis

Top Keywords

dyspepsia drugs
12
drugs dyspepsia
8
drugs
6
self-medication
5
dyspepsia
5
self-medication dyspepsia
4
dyspepsia appropriate
4
appropriate it?
4
it? background
4
background scope
4

Similar Publications

Hemp Extract () in the Treatment of Gastrointestinal Distress and Dyspepsia: Historical Insights from Barcelona, Spain.

Pharmaceuticals (Basel)

November 2024

European Union Traditional Cannabis Medicines (EUTC) Research, 08001 Barcelona, Spain.

This study explores the trajectory of interest in and use of (hemp extract, i.e., extract of L.

View Article and Find Full Text PDF

Randomized clinical trial: the effects of mirtazapine in functional dyspepsia patients.

Therap Adv Gastroenterol

January 2025

Center of Health Management, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong 250012, China.

Background: Functional dyspepsia (FD) is one of the most common gastrointestinal disorders worldwide. Currently, anti-gastric drugs, gastric acid inhibitors, prokinetic drugs, and mucosal protective drugs are widely used in FD patients, however, only a small proportion of patients benefit from these drugs. Studies reported mirtazapine may improve symptoms of FD patients but the efficacy and safety of mirtazapine in the treatment of FD is unclear.

View Article and Find Full Text PDF
Article Synopsis
  • A study examined the effectiveness and safety of Aurantii Fructus Immaturus flavonoid (AFIF) tablets compared to domperidone for treating functional dyspepsia (FD).
  • After 4 weeks of treatment, both AFIF and domperidone showed similar rates of symptom relief, but AFIF had a significantly higher rate of symptom disappearance 4 weeks after stopping treatment.
  • The AFIF group also experienced fewer adverse events, suggesting a better safety profile compared to domperidone.
View Article and Find Full Text PDF

Disorders of gut-brain interaction (DGBI), formerly known as functional bowel disorders, encompass a diverse array of conditions and symptoms that may manifest in different parts of the gastrointestinal tract. Some of the most prevalent DGBIs include functional dyspepsia, irritable bowel syndrome, functional constipation, functional diarrhea, and functional bloating and distension. Around 80% of patients with dyspepsia have no identifiable organic cause and are labeled as functional dyspepsia.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess how Weichang'an pill (WCAP) affects functional dyspepsia (FD) in rats, focusing on brain-gut peptides and gut microbiota as potential treatment mechanisms.
  • Researchers created an FD rat model and divided the rats into different treatment groups, including those receiving WCAP and a control for comparison, then measured gastrointestinal motility and gut microbiota composition.
  • Results showed that WCAP improved FD symptoms by enhancing gastric emptying, regulating brain-gut peptide levels, and restoring gut microbiota balance, suggesting it could be an effective treatment for FD.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!